Shares of Vitalhub Corp. (TSE:VHI – Get Free Report) have received an average recommendation of “Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is C$12.67.
Separately, Canaccord Genuity Group set a C$15.00 price objective on Vitalhub and gave the company a “buy” rating in a report on Friday, August 28th.
Read Our Latest Stock Analysis on VHI
Vitalhub Price Performance
Shares of Vitalhub stock opened at C$7.80 on Wednesday. Vitalhub has a 1-year low of C$6.46 and a 1-year high of C$11.12. The business has a 50-day moving average of C$7.65 and a 200-day moving average of C$7.63. The company has a market capitalization of C$493.43 million, a PE ratio of 65.00, a P/E/G ratio of 1.18 and a beta of 1.40.
Vitalhub (TSE:VHI – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported C$0.03 earnings per share (EPS) for the quarter. Vitalhub had a net margin of 5.89% and a return on equity of 2.79%. The business had revenue of C$31.74 million for the quarter. On average, equities analysts expect that Vitalhub will post 0.23 earnings per share for the current fiscal year.
About Vitalhub
VitalHub is a leading software company dedicated to empowering health and human services providers globally. VitalHub’s comprehensive product suite includes electronic health records, operational intelligence, and workforce automation solutions that serve over 1,300 clients across the UK, Canada, and other geographies. The Company has a robust two-pronged growth strategy, targeting organic opportunities within its product suite and pursuing an aggressive M&A plan. VitalHub is headquartered in Toronto with over 700 employees globally, across key regions and the VitalHub Innovations Lab in Sri Lanka.
Further Reading
- Five stocks we like better than Vitalhub
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Vitalhub Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitalhub and related companies with MarketBeat.com's FREE daily email newsletter.
